# OnCo record paper-checkmate-026-first-line-nivolumab-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-026-first-line-nivolumab-nejm-2017" ;
  schema:name "CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer"@en ;
  schema:description "Giving an immunotherapy drug instead of chemotherapy as the first treatment did not help patients selected only by a moderate level of the PD-L1 protein. It is the trial that showed the threshold, not the drug, was the problem."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1613493>, <https://pubmed.ncbi.nlm.nih.gov/28636851/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1613493> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Carbone DP, Reck M, Paz-Ares L, et al." ;
  onco:related <https://onco.cc/biomarkers/pd-l1-tc-score/>, <https://onco.cc/biomarkers/tmb-high/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/ihc/> ;
  onco:people <https://onco.cc/people/martin-reck/> ;
  onco:journals <https://onco.cc/journals/nejm/> .